翰宇药业：2025年预盈4000万元～5000万元 GLP-1制剂与原料药业务规模大幅放量

Core Viewpoint - Hanyu Pharmaceutical (300199.SZ) expects to achieve a net profit of 40 million to 50 million yuan for the year 2025, a significant turnaround from a loss of 17,365.40 million yuan in the previous year, primarily due to the substantial growth in its GLP-1 formulations and raw material drug business, as well as the advancement of its CRDMO business [1] Group 1 - The company anticipates a net profit attributable to shareholders for 2025, marking a return to profitability after a previous loss [1] - The expected profit increase is driven by the large-scale expansion of the GLP-1 formulations and raw material drug business [1] - The company is also focusing on enhancing the competitiveness of its core products through increased investment in research and development, particularly in the innovative drug HY3003 [1]